	US 12,351,649 B2
	Antibodies to oxidation-specific epitopes
Sotirios Tsimikas, San Diego, CA (US); Joseph Witztum, San Diego, CA (US); and Xuchu Que, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Oct. 13, 2021, as Appl. No. 17/500,794.
Application 17/500,794 is a continuation of application No. 16/330,760, granted, now 11,168,148, previously published as PCT/US2017/050566, filed on Sep. 7, 2017.
Claims priority of provisional application 62/384,694, filed on Sep. 7, 2016.
Prior Publication US 2022/0135704 A1, May 5, 2022
Int. Cl. C07K 16/44 (2006.01); A61P 1/16 (2006.01); A61P 9/10 (2006.01); G01N 33/53 (2006.01)

CPC C07K 16/44 (2013.01) [A61P 1/16 (2018.01); A61P 9/10 (2018.01); G01N 33/5308 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); G01N 2800/085 (2013.01)]

13 Claims

1. An isolated antibody or antibody fragment that binds to an MAA oxidized specific epitope (MAA-OSE), wherein the antibody or antibody fragment comprises: a variable heavy chain (VH) domain and a variable light chain (VL) domain, wherein the VH and VL, respectively, comprise the three heavy chain complementarity determining region (CDR) amino acid sequences and the three light chain CDR amino acid sequences of the VH and VL set forth in SEQ ID NOs: 8 and 6; 16 and 14; or 20 and 18.